Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin

BJU International

Volumn 110, Issue 10, 2012, Pages 1478-1484

  Saito, Kazutaka ^a   Urakami, Shinji ^a   Komai, Yoshinobu ^a   Yasuda, Yosuke ^a   Kubo, Yuichi ^a   Kitsukawa, Shinichi ^a   Okubo, Yuhei ^a   Yamamoto, Shinya ^a   Yonese, Junji ^a   Fukui, Iwao ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

biomarker; C reactive protein; chemotherapy; neoplasm; prognosis; urothelial cancer

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; VISCERAL METASTASIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84868214923     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11153.x     Document Type: Article

References (26)

1. Logothetis CJ, Dexeus FH, Finn L, et al,. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-5 (Pubitemid 20200193)
2. Saxman SB, Propert KJ, Einhorn LH, et al,. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9 (Pubitemid 27289886)
3. Fukui I, Yonese J, Tsukamoto T, et al,. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. Cancer Chemother Pharmacol 2001; 48: 88-93 (Pubitemid 32662442)
4. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N,. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-5 (Pubitemid 27527715)
5. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA,. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-8 (Pubitemid 27485860)
6. von der Maase H, Hansen SW, Roberts JT, et al,. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77
7. Tsukamoto T, Yonese J, Ohkubo Y, Fukui I,. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma. Cancer 2006; 106: 2363-8 (Pubitemid 43787659)
8. Bellmunt J, Theodore C, Demkov T, et al,. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-61
9. Culine S, Theodore C, De Santis M, et al,. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94: 1395-401 (Pubitemid 43772272)
10. Vaughn DJ, Srinivas S, Stadler WM, et al,. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115: 4110-7
11. Bellmunt J, Choueiri TK, Fougeray R, et al,. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-5
12. Albers P, Park SI, Niegisch G, et al,. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22: 288-94
13. Niegisch G, Fimmers R, Siener R, Park SI, Albers P,. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology Trial AB20/99). Eur Urol 2011; 60: 1087-96
14. Roxburgh CS, McMillan DC,. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-63
15. Iimura Y, Saito K, Fujii Y, et al,. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 1004-12
16. Saito K, Tatokoro M, Fujii Y, et al,. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009; 55: 1145-53
17. Hilmy M, Bartlett JM, Underwood MA, McMillan DC,. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005; 92: 625-7 (Pubitemid 40460593)
18. Saito K, Kawakami S, Ohtsuka Y, et al,. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007; 100: 269-73 (Pubitemid 47036572)
19. Yoshida S, Saito K, Koga F, et al,. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008; 101: 978-81 (Pubitemid 351422558)
20. Gakis G, Todenhoefer T, Renninger M, et al,. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011; 108: 1800-5
21. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14 (Pubitemid 11167383)
22. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA, Evaluating the yield of medical tests. JAMA 1982; 247: 2543-6 (Pubitemid 12155954)
23. Ganapathi MK, May LT, Schultz D, et al,. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988; 157: 271-7 (Pubitemid 19004856)
24. Hurlimann J, Thorbecke GJ, Hochwald GM,. The liver as the site of C-reactive protein formation. J Exp Med 1966; 123: 365-78
25. Okamoto M, Hattori K, Oyasu R,. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997; 72: 149-54 (Pubitemid 27314652)
26. Proctor MJ, Morrison DS, Talwar D, et al,. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-41